New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 4, 2014
11:24 EDTVRMLVermillion patent for predictive markers for ovarian cancer posted by USPTO
According to a post to the USPTO site dated March 4, Vermillion applied for a patent for methods for predicting the presence, subtype and stage of ovarian cancer, as well as for assessing the therapeutic efficacy of a cancer treatment and determining whether a subject potentially is developing cancer. Associated test kits, computer and analytical systems as well as software and diagnostic models are also provided in the patent filing.
News For VRML From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 27, 2015
08:06 EDTVRMLVermillion announces initial results from OVA1 clinical trial
Vermillion announced initial results from a cost-effectiveness analysis study, co-authored by Dr. Robert Bristow and Dr. Gareth Forde, clinicians at the UC Irvine and Dr. John Hornberger, a health economist at Stanford University School of Medicine. The analysis reported by Dr. Forde and his colleagues differed from previous studies in that it: Utilized OVA1 test performance characteristics derived directly from two OVA1 clinical trials; Compared cost-effectiveness using only common, validated benchmark protocols and cutoffs; Evaluated a single prospectively enrolled and double-blinded registry study cohort for which each benchmark method was compared on a per-patient basis with OVA1 results; Included an expert treatment decision path analysis, independently published epidemiology and quality of life utility assumptions and a robust hidden Markov model methodology; Considered direct costs from a Medicare reimbursement perspective, and separately, inclusion of indirect costs associated with lost patient and caregiver productivity.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use